Regular formoterol treatment in mild asthma: Effect on bronchial responsiveness during and after treatment

American Journal of Respiratory and Critical Care Medicine

Volumn 152, Issue 4 I, 1995, Pages 1170-1174

  Yates, D H ^b   Sussman, H S ^b   Shaw, M J ^b   Barnes, P J ^b   Chung, K F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; GLUCOCORTICOID; HISTAMINE; METHACHOLINE;

ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; BRONCHUS REACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; NAUSEA; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; TREMOR; VERTIGO;

EID: 0029145693     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.152.4.7551366     Document Type: Article

References (39)

1. Barnes, P. J. New drugs for asthma. 1993. Eur. Respir. J. 5:1126-1136.
2. Tattersfield, A. E. 1993. Clinical pharmacology of long-acting β-receptor agonists. Life Sciences 52:2161-2169.
3. 2-adrenoceptor agonists: a new perspective in the treatment of asthma. Eur. Respir. J. 4:218-226.
4. British Thoracic Society. 1993. Guidelines on the management of asthma. Thorax 48:S1-S24.
5. Vathanen, A. S., A. J. Knox, B. G. Higgins, J. R. Britton, and A. E. Tattersfield. 1988. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1:554-558.
6. Kraan, J., G. H. Koeter, T. H. van der Mark, H. J. Sluiter, K. de Vries. 1985. Changes in bronchial reactivity induced by 4 weeks of treatment with anti-asthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J. Allergy Clin. Immunol. 76:628-636.
7. Kerrebijn, K. F., E. E. M. van Essen-Zandvliet, and H. J. Neijens. 1987. Effect of long term treatment with inhaled corticosteroids and beta agonists on the bronchial responsiveness in children with asthma. J. Allergy Clin. Immunol. 79:653-659.
8. 2-agonist treatment. Am. Rev. Respir. Dis. 148:707-712.
9. van Schayck, C. P., S. J. Graffsam, M. B. Visch, E. Dompeling, C. van Weel, and C. L. van Herwaarden. 1990. Increased bronchial responsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J. Allergy Clin. Immunol. 86:793-800.
10. Sears, M. R., D. R. Taylor, C. G. Print, D. C. Lake, Q. Li, E. M. Flannery, D. M. Yates, M. K. Lucas, and G. P. Herbison. 1990. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336:1391-1396.
11. 2-agonists in asthma. N. Engl. J. Med. 327:1204-1208.
12. 2-agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N. Engl. J. Med. 327:1198-1203.
13. Beach, J. R., C. L. Young, R. Harkawat, P. V. Gardiner, A. J. Avery, G. A. Coward, E. H. Walters, and D. J. Hendrick. 1993. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm. Pharmocol. 6:155-157.
14. 2-agonist salmeterol in mild to moderate asthmatic patients. Thorax 48:1121-1124.
15. 2-adrenoceptor agonist. Allergy 44:264-271.
16. 2-adrenergic receptor agonist: double blind comparison with salbutamol and placebo in children and asthma. J. Allergy Clin. Immunol. 84:891-895.
17. Graaf-Lonnevig, V., and L. Browald. 1990. Twelve hours'bronchodilating effect of inhaled formoterol in children with asthma: a double blind cross-over study versus salbutamol. Clin. Exp. Allergy 20:429-432.
18. 2-agonist formoterol. Am. Rev. Respir. Dis. 143:998-1001.
19. Rabe, K. F., R. Jorres, D. Nowak, N. Behr, and H. Magnussen. 1993. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am. Rev. Respir. Dis. 147:1436-1441.
20. American Thoracic Society. 1987. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am. Rev. Respir. Dis. 136:225.
21. 2-adrenoceptor agonist, against methacholine-induced bronchoconstriction. Br. J. Clin. Pharmacol. 29:321-324.
22. Henriksen, J. M., L. Agertoft, and S. Pedersen. 1992. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J. Allergy Clin. Immunol. 89: 1176-1182.
23. Wong, B. J., J. Dolovich, E. H. Ramsdale, P. O'Byrne, L. Gontovnick, J. A. Denburgh, and F. Hargreave. 1992. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. Am. Rev. Respir. Dis. 146:1156-1160.
24. 2-agonist. J. Allergy Clin. Immunol. 89:844-849.
25. Twentyman, O. P., J. P. Finnergy, A. Harris, J. Palmer, and S. T. Holgate. 1990. Protection against allergen-induced asthma by salmeterol. Lancet 336:1338-1342.
26. von Berg A., and D. Berdel. 1990. Efficacy of formoterol metered aerosol in children. Lung 168(Suppl.):90-98.
27. Worth, H., M. Zimmerman, C. Kleiser, H. Lemoine, and D. Reinhardt. 1993. Long term treatment with formoterol does not induce tachyphylaxis in patients with mild asthma. Eur. Respir. J. 6(Suppl 17):P1233.
28. Gibson, G. J., J. K. Greenacre, P. Konig, M. E. Connolly, and N. B. Pride. 1978. Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma. Br. J. Dis. Chest 72:199-206.
29. Cockroft, D. W., C. P. McFarland, S. A. Britto, V. A. Swustum, and B. A. Rutherford. 1993. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 432:833-837.
30. Ramage, L., B. J. Lipworth, C. G. Ingram, I. A. Cree, and D. P. Dhillon. 1994. Reduced protection against exercise-induced bronchocontstriction after chronic dosing with salmeterol. Respir. Med. 88:363-368.
31. Arvidsson, P., S. Larsson, C-G. Lofdahl, B. Melander, N. Svedmyr, and L. Wahlander. 1991. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur. Respir. J. 4:1168-1173.
32. 2-agonist, inhaled twice daily, in stable asthmatic subjects. Chest 101:1019-1022.
33. Kesten, S., K. R. Chapman, I. Broder, A. Cartier, R. H. Hyland, A. Knight, J. L. Malo, J. A. Mazza, D. W. Moote, P. Small, S. Tarlo, L. Gantovnick, and A. S. Rebuck. 1991. A three month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am. Rev. Respir. Dis. 144:622-625.
34. Palmer, J. B. D., A. M. Stuart, G. L. Shepherd, and K. Viskum. 1992. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease: a 3 month comparison of the efficacy and safety of twice daily salbutamol (100μg) with salmeterol (50 μ8). Respir. Med. 86:409-417.
35. Perlman, D. S., P. Chervinsky, C. LaForce, J. M. Seltzer, D. L. Southern, J. P. Kemp, R. J. Dockhorn, J. Grossman, R. F. Liddle, S. W. Yancey, D. M. Cocchetto, W. J. Alexander, and A. Van As. 1992. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N. Engl. J. Med. 327:1420-1425.
36. Repsher, L. H., J. A. Anderson, R. K. Bush, C. J. Falliers, I. Kass, J. P. Kemp, C. Reed, S. Siegel, and D. R. Webb. 1984. Assessment of tachyphylaxis following prolonged therapy with inhaled albuterol aerosol. Chest 85:34-39.
37. Newnham, D. M., D. G. McDevitt, and B. J. Lipworth. 1994. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am. J. Med. 97:29-37.
38. 2-adrenoceptor subtypes following chronic glucocorticoid treatment in rats (abstract). Am. J. Respir. Crit. Care Med. 149:A484.
39. 2-adrenoceptor gene expression in human lung. Am. Rev. Respir. Dis. 145:A834.